| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
GRI Bio, Inc.$1.74
-0.08 (-4.49%)
D 21Pipeline Score Richly Valued Biotech · Clinical
Market Cap
3.65 M
EPS
-79.55
P/E Ratio
-
Value Trade
81.17 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
361.00 K
Operating CF
-3.69 M
Total Assets
11.34 M
Total Liabilities
794.00 K
Equity
10.54 M
D/E Ratio
12,345
-3.74 %
Week
-21.97 %
1 Month
-19.84 %
3 Month
-96.39 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
11.05 M
Monthly Burn
1.23 M
Runway
7.3 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
26.80 K
52 Week Range
1.97 - 80.36
% held by Insiders
0 %
% held by Institutions
1.59 %
Enterprise Value
-7.34 M
Total Shares
1.44 M
Short %
8.12 %
Float Shares
1.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for GRI Bio, Inc.
240Total events
2Upcoming
45Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 2
Event history 238
Jun 18, 2026
▲Orphan Drug DesignationGRI-0621Designation
FDA grants Orphan Drug Designation for GRI-0621 in IPF
Idiopathic Pulmonary Fibrosissource ↗
May 20, 2026
May 14, 2026
▲Full ResultsGRI-0621Clinical Data
Phase 2a topline results: primary safety endpoint met; exploratory pulmonary function and biomarker data reported
idiopathic pulmonary fibrosissource ↗
May 14, 2026
▲Patent GrantedGRI-0621IP / Competition
Additional patent applications filed based on Phase 2a data
idiopathic pulmonary fibrosissource ↗
May 14, 2026
Apr 8, 2026
▲Patent GrantedIP / Competition
Notice of Allowance for UAE Patent No. P6000687/2017 covering novel type 2 diverse NKT cell agonists
inflammatory conditionssource ↗
Feb 17, 2026
▲Additional DataGRI-0621Clinical Data
Additional positive Phase 2a data including biomarker results
Idiopathic Pulmonary Fibrosissource ↗
Feb 11, 2026
◆Oral PresentationPresentation
GRI Bio to present at Corporate Connect Webinar Series hosted by Webull Financial
Jan 28, 2026
▲Full ResultsGRI-0621Clinical Data
Additional positive Phase 2a gene expression data announced
Idiopathic Pulmonary Fibrosissource ↗
Jan 26, 2026
▲Patent GrantedIP / Competition
USPTO issued U.S. Patent No. 12,528,775 covering novel compound compositions
Drug Pipeline Intelligence
D21
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 19%
Micro Cap (rank 739 of 911)
Percentile RankGRI Bio, Inc. faces pipeline headwinds (21/100), with $76M risk-adjusted pipeline value, led by Tazarotene in Idiopathic Pulmonary Fibrosis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tazarotene Small molecule | Idiopathic Pulmonary Fibrosis | Phase 2 | NCT06331624 | 8% | $76M | COMPLETED | 35 | - | - | Sep 30, 2025 | - | Oct 30, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
GRI-0621 Orphan | idiopathic pulmonary fibrosis | Phase 2a | 2026-05-14 | zero cough active vs placebo: 0% vs. 25%; dyspnea reduction: 76% (4% vs. 17%); weight loss active vs placebo: 0% vs. 17%; diarrhea reduction: 61% (13% vs. 33%); fvc improvement: +99 mL overall, +139 mL in SOC combination subset Read More | GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline Read More | |
GRI-0621 Orphan | idiopathic pulmonary fibrosis | Phase 2a | 2026-05-14 | zero cough active vs placebo: 0% vs. 25%; dyspnea reduction: 76% (4% vs. 17%); weight loss active vs placebo: 0% vs. 17%; diarrhea reduction: 61% (13% vs. 33%); fvc improvement: +99 mL overall, +139 mL in SOC combination subset Read More | GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline Read More | |
GRI-0621 Orphan | idiopathic pulmonary fibrosis | Phase 2a | 2026-05-14 | zero cough active vs placebo: 0% vs. 25%; dyspnea reduction: 76% (4% vs. 17%); weight loss active vs placebo: 0% vs. 17%; diarrhea reduction: 61% (13% vs. 33%); fvc improvement: +99 mL overall, +139 mL in SOC combination subset Read More | GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GRI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GRI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GRI▼ -19%on this news
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRI Bio has secured FDA Orphan Drug Designation for GRI-0621, an investigational therapy for Idiopathic Pulmonary Fibrosis (IPF). This designation highlights the drug's potential to meet significant unmet medical needs in treating this progressive lung disease. GRI-0621's unique mechanism of action and positive Phase 2a trial results further support its development and potential market impact.
Read more →GRI▲ +5.4%on this news
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
GRI Bio, Inc. announced that its CEO, Marc Hertz, will present at A.G.P.'s Annual Healthcare Company Showcase on May 20, 2026. The company focuses on developing Natural Killer T (NKT) cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. This webcast will provide insights into GRI Bio's immune-modulating pipeline and its lead program, GRI-0621, which targets idiopathic pulmonary fibrosis. The event emphasizes GRI Bio's commitment to combating unmet medical needs in serious health conditions.
Read more →GRIGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRI Bio reported strong results for Q1 2026, highlighting the Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis (IPF). The study demonstrated notable efficacy, including zero cough and significantly lower treatment-related diarrhea compared to placebo, alongside improvements in dyspnea and lung function. Additionally, the company is advancing GRI-0803 towards IND-enabling activities targeting autoimmune diseases. With approximately $11 million in cash, GRI Bio is positioned for continued development and regulatory planning.
Read more →GRIGRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
GRI Bio, Inc. has announced the receipt of a Notice of Allowance for a UAE patent covering novel type 2 diverse NKT cell agonists aimed at treating inflammatory conditions. This development enhances the company's global intellectual property protections and signifies its commitment to expanding its presence in the growing healthcare market in the UAE and the broader MENA region. The patent supports GRI Bio's focus on modulating immune responses that target a range of diseases with significant unmet needs. Furthermore, it positions the company to explore future partnerships and licensing opportunities.
Read more →GRIGRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
GRI Bio, Inc. participated in a Virtual Investor segment featuring CEO Marc Hertz. He discussed promising Phase 2a data for the treatment of Idiopathic Pulmonary Fibrosis (IPF), highlighting significant biomarker improvements related to fibrosis and lung repair. The company focuses on developing therapies targeting Natural Killer T cells to address inflammatory and autoimmune diseases.
Read more →GRIGRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
GRI Bio, Inc. participated in a Virtual Investor segment featuring CEO Marc Hertz, who discussed the company's recent positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF). The data highlighted significant biomarker improvements related to fibrosis and lung repair. GRI Bio focuses on developing therapies targeting Natural Killer T cells to treat various inflammatory and fibrotic diseases.
Read more →GRI▼ -17%on this news
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
GRI Bio, Inc. will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 11, 2026. The presentation will be led by CEO Marc Hertz and aims to highlight the company's advancements in immune cell modulators for treating inflammatory and autoimmune diseases. GRI Bio's innovative pipeline includes therapies targeting Natural Killer T cells, with a focus on idiopathic pulmonary fibrosis.
Read more →GRI▼ -17%on this newsshared move
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
GRI Bio reported its financial results for the year ending December 31, 2025, highlighting a cash position of $8.2 million and an additional $6.5 million raised in January 2026. The company emphasized strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis and ongoing development of GRI-0803 for autoimmune diseases. Despite a net loss of $12 million, GRI Bio aims to fund operations into Q1 2027.
Read more →GRI▼ -19.2%on this news· ran to -37% by day 3
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
GRI Bio announced promising results from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF). The new RNA-sequencing data indicates significant improvements in gene expression linked to lung injury and fibrosis repair. These findings suggest GRI-0621 may offer a novel approach to treating IPF by promoting lung regeneration rather than merely managing symptoms.
Read more →GRIGRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
GRI Bio has been granted a new U.S. patent for novel compound structures that enhance its immunomodulator platform. This patent strengthens the company's intellectual property and supports its development of therapies for inflammatory, fibrotic, and autoimmune diseases. GRI Bio is focused on advancing its lead program, GRI-0621, which targets idiopathic pulmonary fibrosis.
Read more →GRIGRI Bio Announces Reverse Stock Split
GRI Bio, Inc. has announced a 1-for-28 reverse stock split, with the aim of boosting its share price to comply with Nasdaq's minimum bid price requirements. The split will take effect on January 23, 2026, and trading under the new share structure will begin on January 26, 2026. This measure follows stockholder approval at a special meeting on January 15, 2026, and aims to enhance market performance amid ongoing challenges. In conjunction, GRI Bio continues to develop its pipeline focused on treatments for inflammatory and autoimmune diseases.
Read more →GRIGRI Bio Announces Reverse Stock Split GRI's common stock is expected to begin trading on a post-split adjusted basis on
GRI Bio, Inc. has announced a 1-for-28 reverse stock split approved by its board of directors and stockholders. This move is intended to increase the trading price of GRI's common stock, helping the company to regain compliance with Nasdaq listing requirements. The reverse split will take effect on January 23, 2026, and will reduce the number of outstanding shares from approximately 15 million to around 536,000. GRI Bio continues to focus on developing therapies for inflammatory, fibrotic, and autoimmune diseases.
Read more →GRIGRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
GRI Bio has announced additional positive findings from its Phase 2a study of GRI-0621, aimed at treating Idiopathic Pulmonary Fibrosis (IPF). The new immune profiling data indicates a positive immunomodulatory effect and improvement in lung function. The treatment demonstrated a differentiated safety profile and met both primary and secondary endpoints, suggesting its potential as a disease-modifying therapy. This data reinforces the clinical proof-of-concept for GRI-0621, emphasizing its effectiveness in targeting the underlying mechanisms of IPF.
Read more →GRIGRI Bio Announces Closing of $8.0 Million Public Offering
GRI Bio, Inc. has successfully closed a public offering raising approximately $8.0 million, which will be utilized for product development and general corporate purposes. The offering consisted of 10,666,667 shares and associated Series F Warrants, set at a price of $0.75 per share. While the company is positioned to advance its innovative pipeline targeting inflammatory and autoimmune diseases, there remain uncertainties regarding the potential exercise of the Series F Warrants and market conditions for future financing. GRI Bio aims to leverage these proceeds to further its clinical advancements, particularly in therapies utilizing Natural Killer T cells.
Read more →GRI▼ -56.5%on this newsshared move
GRI Bio Announces Pricing of $8,000,000 Public Offering
GRI Bio, Inc. has announced the pricing of a public offering totaling $8 million, consisting of 10,666,667 shares and Series F Warrants. The offering is expected to close on December 12, 2025, subject to customary conditions. Proceeds will be used for product development and general corporate purposes. The company focuses on therapies for inflammatory and autoimmune diseases.
Read more →GRI▼ -56.5%on this newsshared move
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
GRI Bio, Inc. has announced a public offering priced at $0.75 per share, aiming to raise approximately $8 million. The offering includes 10,666,667 shares and Series F warrants, which will expire in five years. The proceeds will support product development and general corporate purposes. The offering is subject to customary closing conditions.
Read more →GRI▼ -56.5%on this newsshared move
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio announced positive topline results from its Phase 2a study of GRI-0621 for treating Idiopathic Pulmonary Fibrosis (IPF). The study met both primary and secondary endpoints, showing that GRI-0621 was well tolerated and led to improvements in biomarkers indicating fibrosis resolution. Additionally, a notable percentage of patients experienced an increase in forced vital capacity compared to those on placebo.
Read more →GRI▲ +31.4%on this news
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio reported positive interim results from its Phase 2a study of GRI-0621 for treating Idiopathic Pulmonary Fibrosis (IPF). At the 6-week mark, patients showed no decline in lung function, and biomarker data indicated potential anti-fibrotic effects. The study remains on schedule for topline data in Q3 2025, with safety assessments showing no concerns.
Read more →GRIGRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GRI Bio, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. CEO Dr. Marc Hertz will lead the presentation, focusing on the company's innovative pipeline targeting inflammatory and autoimmune diseases. The event will also allow for in-person meetings with investors, enhancing engagement opportunities.
Read more →GRI▲ +10.8%on this news
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GRI Bio, Inc. will present at the Webull Financial Corporate Connect Webinar Series on August 20, 2025. The presentation will be led by CEO Marc Hertz, focusing on GRI Bio's innovative therapies targeting Natural Killer T cells for treating inflammatory and autoimmune diseases. This event highlights GRI Bio's commitment to addressing significant medical needs.
Read more →GRIGRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
GRI Bio, Inc. participated in a Virtual Investor segment where CEO Marc Hertz discussed the company's recent interim biomarker data from a Phase 2a study in Idiopathic Pulmonary Fibrosis. The company focuses on developing therapies targeting Natural Killer T cells to treat inflammatory and fibrotic diseases. Their lead program, GRI-0621, aims to address the unmet needs in IPF treatment.
Read more →GRIGRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
GRI Bio, Inc. participated in a Virtual Investor segment where CEO Marc Hertz discussed interim biomarker data from their ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis. The company is developing therapies targeting Natural Killer T cells to treat inflammatory and fibrotic diseases. Their lead program, GRI-0621, aims to address significant unmet needs in IPF treatment.
Read more →GRI▼ -37.6%on this newsshared move
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio, Inc. reported positive interim results from its ongoing Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF). The Independent Data Monitoring Committee recommended continuing the study, noting no safety concerns. The interim analysis showed promising reductions in biomarkers related to fibrogenesis and improvements in collagen remodeling compared to the control group. Topline results are expected in Q3 2025, alongside further pulmonary function tests.
Read more →GRIGRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
GRI Bio, Inc. participated in the Virtual Investor 'What’s Your Story' Summer Spotlight On-Demand Conference. CEO Marc Hertz shared insights into his dedication to the company and its innovative pipeline of Natural Killer T cell modulators aimed at treating inflammatory and autoimmune diseases. The on-demand video is available on the company's website.
Read more →GRIGRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
GRI Bio, Inc. participated in the Virtual Investor 'What’s Your Story' Summer Spotlight On-Demand Conference, where CEO Dr. Marc Hertz discussed his commitment to the company and its innovative pipeline targeting inflammatory and autoimmune diseases. The on-demand video is available on their website, highlighting GRI Bio's focus on Natural Killer T cell modulators and their lead program for idiopathic pulmonary fibrosis.
Read more →GRI▲ +6.2%on this news
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio has completed patient enrollment for its Phase 2a study of GRI-0621, targeting Idiopathic Pulmonary Fibrosis (IPF). Interim safety results indicate that GRI-0621 is safe and well-tolerated. The company anticipates reporting interim biomarker results in July 2025, with topline data expected in Q3 2025.
Read more →GRI▼ -5.2%on this newsshared move
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio reported positive interim safety results for GRI-0621 in its Phase 2a study for idiopathic pulmonary fibrosis. The Independent Data Monitoring Committee has recommended the continuation of the study, noting no safety concerns in the first 24 patients evaluated. GRI-0621 was found to be safe and well-tolerated, with no adverse events related to lipid levels. Topline data is expected in Q3 2025.
Read more →GRI▼ -5.2%on this newsshared move
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio has reported encouraging interim safety results for its GRI-0621 treatment in a Phase 2a study for idiopathic pulmonary fibrosis (IPF). The Independent Data Monitoring Committee found no safety concerns after evaluating the first 24 patients. The ongoing study aims to enroll 36 subjects and is expected to deliver 6-week interim biomarker results by July 2025, with topline data following in Q3 2025. The findings indicate potential for GRI-0621 as a novel oral therapeutic for IPF, addressing significant unmet medical needs in this area.
Read more →GRI▼ -9.4%on this news
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
GRI Bio presented positive preclinical data for GRI-0621, demonstrating its potential to resolve inflammation and fibrosis in pulmonary fibrosis. The interim analysis from the ongoing Phase 2a study indicates that GRI-0621 is safe and well-tolerated, with promising effects on biomarkers associated with the disease. The company anticipates further results in Q3 2025.
Read more →GRIGRI Bio to Participate in the Virtual Investor Closing Bell Series
GRI Bio, Inc. will participate in the Virtual Investor Closing Bell Series on May 28, 2025. CEO Marc Hertz will present a corporate overview and business outlook, with a live Q&A session for investors. The event will be webcast live and available for replay for 90 days.
Read more →GRIGRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
GRI Bio, Inc. will present at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025. CEO Marc Hertz will participate in a live webcast fireside chat, discussing the company's innovative pipeline of Natural Killer T cell modulators aimed at treating inflammatory and autoimmune diseases. The event underscores GRI Bio's commitment to addressing significant medical needs.
Read more →GRIGRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GRI Bio, Inc. announced that its CEO, Marc Hertz, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025. The company is focused on developing therapies to treat inflammatory, fibrotic, and autoimmune diseases, primarily through the modulation of Natural Killer T cells. Its lead program, GRI-0621, aims to provide a novel oral treatment for idiopathic pulmonary fibrosis, addressing a critical unmet medical need. The company boasts a diverse pipeline and a significant proprietary compound library.
Read more →GRIGRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
GRI Bio, Inc. has reported its first quarter 2025 financial results and confirmed that its Phase 2a trial for GRI-0621, targeting Idiopathic Pulmonary Fibrosis (IPF), is on track. The trial has already shown positive interim safety and biomarker results, and patient enrollment for a 6-week interim analysis has been completed. Additionally, GRI Bio has sufficient cash to fund operations through Q3 2025. Upcoming milestones include more data expected to be released in Q2 and Q3 of 2025.
Read more →GRI▼ -10.6%on this news
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio reported positive interim biomarker data from its Phase 2a study of GRI-0621 for treating Idiopathic Pulmonary Fibrosis (IPF). The Independent Data Monitoring Committee recommended continuing the study, noting no safety concerns. The study is on track for interim results in Q2 2025 and topline data in Q3 2025.
Read more →GRI▼ -10.6%on this newsshared move
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio, Inc. announced positive interim biomarker data from its ongoing Phase 2a study of GRI-0621 for treating Idiopathic Pulmonary Fibrosis (IPF). The Independent Data Monitoring Committee (IDMC) recommended continuing the study, noting no safety concerns among the first 12 patients evaluated. With more than 70% of patients enrolled, the company anticipates interim results in Q2 2025 and topline data later in Q3 2025. The findings suggest a promising anti-fibrotic effect associated with the treatment.
Read more →GRI▼ -6.3%on this news· ran to -19% by day 3shared move
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio, Inc. has completed enrollment for its Phase 2a study evaluating GRI-0621 for idiopathic pulmonary fibrosis (IPF), achieving 24 out of 36 planned patients. The company anticipates reporting interim biomarker data from the first 12 patients shortly, with topline results expected in the third quarter of 2025. Initial interim safety data indicate that GRI-0621 is safe and well-tolerated. This trial is crucial as it explores treatment options for a severe condition with significant unmet needs.
Read more →GRIGRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
GRI Bio, Inc. announced that its abstract has been selected for a poster discussion session at the 2025 American Thoracic Society International Conference. The presentation will focus on the role of iNKT cells in pulmonary fibrosis, highlighting GRI Bio's commitment to innovate treatments for inflammatory and autoimmune diseases. The poster will be presented by CEO Marc Hertz, emphasizing the significance of their research pipeline in addressing unmet medical needs.
Read more →GRI▼ -17.3%on this news· ran to -31% by day 3
GRI Bio Announces Closing of $5.0 Million Public Offering
GRI Bio, Inc. announced the successful closing of a $5.0 million public offering. The offering included 1,388,888 shares of common stock, along with related Series E-1, E-2, and E-3 warrants. The company plans to use the proceeds for developing its product candidates and general corporate purposes. The registration statement for the offering was declared effective by the SEC on April 1, 2025. GRI Bio is focused on advancing therapies for inflammatory, fibrotic, and autoimmune diseases.
Read more →GRI▼ -36.9%on this newsshared move
GRI Bio Announces Pricing of $5.0 Million Public Offering
GRI Bio, Inc. has announced the pricing of a public offering amounting to $5.0 million, which includes 1,388,888 shares and various Series Warrants. The closing of the offering is anticipated around April 2, 2025, contingent on customary conditions. Proceeds from this offering are intended to support the development of its product candidates, alongside working capital needs. While the company could gain further funding from the exercise of the Series Warrants, uncertainties remain regarding their exercise and the company's future financing capabilities.
Read more →GRI▼ -36.9%on this newsshared move
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio, Inc. reported interim results from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF), highlighting that the treatment is safe and well-tolerated in the first 12 patients evaluated. The Independent Data Monitoring Committee recommended continuing the study without safety concerns. With interim biomarker data expected by Q2 2025, topline results are anticipated in Q3 2025, indicating the company's ongoing commitment to addressing the significant unmet needs in IPF treatment.
Read more →GRI▼ -26.7%on this news· ran to -67% by day 3shared move
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
GRI Bio, Inc. has announced the granting of two global patents aimed at expanding its intellectual property portfolio. These patents focus on novel treatments for autoimmune and inflammatory diseases, specifically targeting type 2 diverse NKT cells. The company is moving forward with its lead program, GRI-0621, which is currently in a Phase 2a clinical trial, with interim data expected in mid-2025. This progress represents GRI Bio's commitment to addressing significant medical needs within its therapeutic focus areas.
Read more →GRI▲ +16%on this news· ran to +47% by day 3
GRI Bio Participates in a Virtual Investor CEO Connect Segment
GRI Bio announced the participation of CEO Marc Hertz in a Virtual Investor CEO Connect segment, discussing the company's pipeline of NKT cell modulators targeting inflammatory and autoimmune diseases. The focus was on GRI-0621, a leading program for Idiopathic Pulmonary Fibrosis, with important interim and topline data expected in the upcoming quarters. The company highlights its innovative approaches in treating serious health conditions, though it must navigate various operational risks.
Read more →GRI▼ -6.2%on this news· ran to +17% by day 3shared move
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio, Inc. reported its financial results for the fiscal year ending December 31, 2024, signaling significant progress in the development of its lead drug GRI-0621 for idiopathic pulmonary fibrosis (IPF). The company anticipates interim and topline data readouts from a Phase 2a study in the second and third quarters of 2025, respectively. Despite a reported net loss of $8.2 million for the year, GRI Bio has sufficient cash reserves to fund operational needs into the second quarter of 2025. Additionally, recent positive preclinical results have bolstered confidence in the drug's potential efficacy and market impact.
Read more →GRI▼ -5.2%on this news
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule
GRI Bio, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price rule, as confirmed by a notice received on March 10, 2025. The company is focused on developing therapies targeting Natural Killer T cells for inflammatory, fibrotic, and autoimmune diseases. GRI Bio's lead program, GRI-0621, is aimed at treating idiopathic pulmonary fibrosis, addressing a critical medical need.
Read more →GRI▼ -5.2%on this newsshared move
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule
GRI Bio, Inc. has announced the regaining of compliance with Nasdaq's minimum bid price requirement. This development signifies a positive turnaround for the clinical-stage biopharmaceutical company, known for its innovative therapies targeting key immune responses in inflammatory and autoimmune diseases. GRI Bio's lead program, GRI-0621, aims to address the unmet needs of patients with idiopathic pulmonary fibrosis. The company continues to develop a promising pipeline, enhancing its position in the biopharmaceutical market.
Read more →GRIGRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference
GRI Bio, Inc. participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference, where CEO Marc Hertz discussed the company's innovative pipeline targeting inflammatory and autoimmune diseases. The presentation emphasized the potential of GRI's therapies, particularly its lead program GRI-0621 for idiopathic pulmonary fibrosis. The on-demand video is available for viewing on the company's website.
Read more →GRIGRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
GRI Bio, Inc. has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference, where CEO Marc Hertz outlined the company's value proposition for 2025. GRI Bio focuses on developing Natural Killer T cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. Their lead therapeutic candidate, GRI-0621, is targeting idiopathic pulmonary fibrosis, addressing a critical unmet medical need in the market. The company's successful participation in such an event underscores its commitment to engaging with the investment community and promoting its innovative pipeline.
Read more →GRIGRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
GRI Bio, Inc. announced that the European Patent Office has issued a decision to grant a patent for GRI-0803 as part of its intellectual property strategy. This patent covers a novel activator for type 2 NKT cells aimed at treating systemic lupus erythematosus (SLE). The company has also made significant advancements in developing its lead program, GRI-0621, which is currently in Phase 2a trials for idiopathic pulmonary fibrosis (IPF). The anticipated patent grant will take effect on January 16, 2025, with further development plans for its product candidates contingent on funding.
Read more →GRIGRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio presented promising preclinical data on GRI-0621 at the 8th Annual Antifibrotic Drug Development Summit. The data indicate that GRI-0621 can reduce inflammation and fibrosis in Idiopathic Pulmonary Fibrosis (IPF) by inhibiting iNKT cell activity. A Phase 2 study is currently underway, with interim results expected in early 2025.
Read more →GRIGRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio, Inc. has presented positive preclinical data on its lead drug candidate, GRI-0621, indicating its potential to reduce inflammation and fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF). At the recent Antifibrotic Drug Development Summit, CEO Marc Hertz highlighted the necessity of effective therapies for fibrotic diseases and expressed confidence in their approach. The company is currently conducting a Phase 2 study to further evaluate GRI-0621's efficacy, with results expected in the coming year.
Read more →GRIGRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
GRI Bio announced its third quarter financial results for 2024, reporting a net loss of $6.3 million. The company raised $13.9 million to extend its cash runway into mid-Q1 2025, allowing continued development of its lead candidate, GRI-0621, for idiopathic pulmonary fibrosis (IPF). Interim data from the Phase 2a study is expected in Q1 2025, with topline results anticipated in Q2 2025, alongside positive preclinical data showing GRI-0621's potential effectiveness. Additionally, the company has expanded its intellectual property protections and is authorized to conduct studies in Australia.
Read more →GRIGRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
GRI Bio has successfully raised $13.9 million in gross proceeds since January 2024, primarily through the exercise of warrants. This funding is expected to extend the company's cash runway into mid Q1 2025, allowing it to advance its lead program, GRI-0621, for treating Idiopathic Pulmonary Fibrosis. The company anticipates upcoming interim and topline data in the following quarters, positioning itself strongly in a market with limited treatment options.
Read more →GRIGRI Bio Announces Exercise of Warrants
GRI Bio, Inc. has announced definitive agreements for the exercise of certain existing warrants, allowing for the purchase of 762,236 shares of common stock at a reduced price of $1.00 per share. This initiative is set to close on or about October 22, 2024, and is expected to generate gross proceeds of approximately $0.8 million. The newly issued Series D-1 and D-2 warrants will support the company's ongoing efforts in developing therapies for inflammatory, fibrotic, and autoimmune diseases.
Read more →GRI▲ +25.4%on this news· ran to +257% by day 3shared move
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio, Inc. has announced promising preclinical data for GRI-0621, which demonstrates its ability to inhibit invariant natural killer T (iNKT) cell activity and potentially improve outcomes in patients with idiopathic pulmonary fibrosis (IPF). The findings were shared at the 22nd International Colloquium on Lung and Airway Fibrosis, highlighting the drug's efficacy in reducing key inflammatory and fibrotic factors. GRI Bio is moving forward with a Phase 2a biomarker study, with interim data expected in late 2024 and topline results anticipated in early 2025.
Read more →GRIGRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
GRI Bio, Inc. (NASDAQ: GRI) has announced that its abstract has been accepted for a poster presentation at the upcoming 22nd International Colloquium on Lung and Airway Fibrosis in Athens, Greece, scheduled for October 12-16, 2024. The presentation will focus on the involvement of Type 1 Invariant Natural Killer T Cells in lung fibrosis, aiming to advance understanding in this critical area. This acknowledgment at a significant international event highlights the company's commitment to improving treatments for inflammatory and fibrotic diseases.
Read more →GRIGRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
GRI Bio, a biotechnology company, has received a patent approval from the Japan Patent Office for its innovative Natural Killer T (NKT) cell modulators aimed at treating inflammatory conditions. This includes methods for modulating invariant NKT cells, which are vital in the treatment of diseases like idiopathic pulmonary fibrosis and systemic lupus erythematosus. The patent positions GRI to leverage Japan's lucrative pharmaceutical market, which is marked by a high prevalence of chronic diseases. The company is advancing its lead candidate, GRI-0621, through Phase 2a trials, with interim data expected soon.
Read more →GRIGRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia
GRI Bio has been authorized by the Australian Medicines and Healthcare products Regulatory Agency (MHRA) and the Human Research Ethics Committee (HREC) to conduct a Phase 2a biomarker study for GRI-0621 in patients with Idiopathic Pulmonary Fibrosis (IPF). This approval will facilitate patient enrollment and extend the company’s clinical development globally. GRI Bio plans to release interim results by Q4 2024 and topline results by Q1 2025, furthering its commitment to treating IPF, a disease with significant unmet needs and limited treatment options.
Read more →GRIGRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
GRI Bio, Inc. will participate in a Virtual Investor CEO Connect segment on October 2, 2024, where CEO Marc Hertz will present and engage with investors. The presentation will focus on the company's innovative pipeline of NKT cell modulators for treating inflammatory, fibrotic, and autoimmune diseases. Investors will have the chance to ask questions live, contributing to an interactive session that highlights GRI Bio's development efforts and commitment to transparency.
Read more →GRIGRI Bio Participates in Virtual Investor KOL Connect Segment
GRI Bio, Inc. participated in a Virtual Investor KOL Connect segment featuring Dr. Helen Parfrey, discussing the treatment of idiopathic pulmonary fibrosis (IPF). The company is advancing GRI-0621, which is currently in a Phase 2a biomarker study. Interim data is expected in Q4 2024, with topline results anticipated in Q1 2025. GRI-0621 is designed as a therapeutic solution to halt disease progression in a condition with very few existing treatment options.
Read more →GRIGRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GRI Bio, Inc. (NASDAQ: GRI) announced its CEO, Marc Hertz, will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. In addition to the presentation, the management team will hold one-on-one meetings with qualified investors. The conference aims to showcase GRI Bio's innovative pipeline of Natural Killer T (NKT) cell modulators targeting inflammatory, fibrotic, and autoimmune diseases. The presentation will be available on-demand after the event.
Read more →GRIGRI Bio to Present at the 2024 European Respiratory Congress
GRI Bio, Inc. announced that its abstract will be presented at the 2024 European Respiratory Congress in Vienna. The poster, titled 'Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis', will explore the role of iNKT cells in pulmonary fibrosis. The presentation is scheduled for September 9, 2024, showcasing GRI Bio's commitment to advancing treatment options for fibrotic and autoimmune diseases. This event highlights the company's innovative research and development efforts in the biopharmaceutical sector.
Read more →GRIGRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GRI Bio has released its financial results for Q2 2024, highlighting progress in its lead program GRI-0621 aimed at treating Idiopathic Pulmonary Fibrosis (IPF). The company is on schedule to report interim results from a Phase 2a biomarker study by the end of 2024. Additionally, GRI Bio has secured a patent in Korea and generated gross proceeds of $4.0 million from a recent public offering. Despite a recorded net loss, the company expresses confidence in its cash reserves to support operations into early 2025.
Read more →GRIGRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
GRI Bio, Inc. (NASDAQ: GRI) will participate in the Virtual Investor Lunch Break Series on July 17, 2024. CEO Marc Hertz is set to provide a corporate overview and discuss the company's business outlook during the event. Investors will have a chance to submit questions, making it interactive. GRI Bio focuses on developing therapies for inflammatory, fibrotic, and autoimmune diseases using Natural Killer T (NKT) cell modulators.
Read more →GRIGRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
GRI Bio, Inc. has released a Virtual Investor segment featuring CEO Marc Hertz discussing interim data from their Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF). The company focuses on developing Natural Killer T cell modulators to treat inflammatory and fibrotic diseases. Their lead program, GRI-0621, aims to address significant unmet needs in IPF treatment.
Read more →GRIGRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
GRI Bio, Inc. has released a Virtual Investor segment featuring CEO Marc Hertz discussing the interim data from their ongoing Phase 2a biomarker study targeting Idiopathic Pulmonary Fibrosis (IPF). The segment highlights the significance of their lead program, GRI-0621, which aims to provide a novel oral therapeutic option for this serious condition. GRI Bio is focused on developing NKT cell modulators, presenting a unique approach to treating inflammatory, fibrotic, and autoimmune diseases. The company also has a range of other potential treatments in development.
Read more →GRIGRI Bio Regains Compliance with Nasdaq
GRI Bio, Inc. has announced that it regained compliance with Nasdaq listing standards, leading to the cancellation of a scheduled hearing. This development allows the company to concentrate on its core business of developing innovative therapies targeting inflammatory, fibrotic, and autoimmune diseases. CEO Marc Hertz expressed optimism about advancing their product candidates, particularly for serious conditions like idiopathic pulmonary fibrosis and systemic lupus erythematosus.
Read more →GRIGRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
GRI Bio announced the publication of positive preclinical data indicating that GRI-0621, a treatment for Idiopathic Pulmonary Fibrosis (IPF), effectively activates NKT cells and reduces lung fibrosis in animal models. The study, published in the American Journal of Respiratory and Critical Care Medicine, highlighted improvements in lung histology and decreased markers of fibrosis and inflammation. GRI Bio is advancing GRI-0621 to a Phase 2a biomarker study, with interim data anticipated by Q3 2024 and topline results expected in Q4 2024. This represents a promising step forward in addressing the unmet therapeutic needs of IPF patients.
Read more →GRIGRI Bio to Present at the 8th Annual IPF Summit
GRI Bio, Inc. will present at the 8th Annual IPF Summit in Boston, MA, on August 22, 2024. Chief Scientific Officer Vipin Kumar Chaturvedi will discuss the therapeutic potential of Natural Killer T (NKT) cell targeting for inflammatory and fibrotic diseases. The company's approach aims to address critical health issues in idiopathic pulmonary fibrosis and systemic lupus erythematosus. GRI Bio's innovative therapies focus on modulating the immune response through NKT cells, showcasing its commitment to advancing treatment options in these areas.
Read more →GRIGRI Bio Announces Closing of $4.0 Million Public Offering
GRI Bio, Inc. has announced the successful closing of a $4.0 million public offering, which includes the sale of shares and Series Warrants. The offering aims to support the company's innovative pipeline focused on Natural Killer T cell modulators for treating various diseases. Additionally, the Series Warrants could provide up to $8.0 million if fully exercised, although there are no guarantees they will be converted to cash. Proceeds from the offering will be used for product development and general corporate needs.
Read more →GRIGRI Bio Announces Pricing of $4.0 Million Public Offering
GRI Bio has announced a public offering of 2,185,793 shares priced at $1.83 each, aiming to raise approximately $4 million. The company plans to utilize the proceeds for its product development and general corporate purposes. The offering includes Series Warrants which could potentially increase gross proceeds by $8 million if fully exercised. However, the company faces certain risks including compliance with Nasdaq listing requirements and uncertainty regarding the exercise of the Series Warrants.
Read more →GRIGRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
GRI Bio has announced that it has been granted a new patent in Korea for its proprietary Natural Killer T (NKT) cell modulators. This patent enhances the company’s intellectual property estate and covers methods for treating inflammatory and autoimmune diseases. GRI Bio's lead program, GRI-0621, is under development for Idiopathic Pulmonary Fibrosis and is expected to deliver interim data in the upcoming quarter. The company is positioning itself to address high-value indications in need of innovative treatment options.
Read more →GRIGRI Bio Announces Pricing of $4 Million Public Offering
GRI Bio, Inc. has announced the pricing of a public offering set to raise approximately $4 million through the sale of over 2 million shares along with accompanying Series Warrants. The offering is aimed at funding the development of the company's product candidates targeting inflammatory, fibrotic, and autoimmune diseases. The Series Warrants have the potential to add an estimated $8 million if exercised. The closing of this offering is anticipated to occur by June 28, 2024, subject to customary closing conditions.
Read more →GRIGRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
GRI Bio, Inc. (NASDAQ: GRI) will present at the Virtual Investor Pitch Conference on June 18, 2024, at 11:00 AM ET. CEO Marc Hertz will give an elevator pitch detailing the company's milestones and therapies targeting inflammatory and autoimmune diseases. The event will allow for live questions from investors, with a replay available for 90 days post-presentation. GRI Bio focuses on NKT cell modulators aimed at treating conditions like idiopathic pulmonary fibrosis and systemic lupus erythematosus.
Read more →GRIGRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
GRI Bio recently participated in a virtual investor segment discussing positive preclinical data for its therapies targeting idiopathic pulmonary fibrosis (IPF) and systemic lupus erythematosus (SLE). The company highlighted upcoming milestones for its drug candidates, including interim data reports and IND filings. GRI Bio aims to advance its innovative pipeline of Natural Killer T cell modulators.
Read more →GRIGRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
GRI Bio, Inc. has participated in a Virtual Investor segment discussing positive preclinical data for its therapies targeting idiopathic pulmonary fibrosis (IPF) and systemic lupus erythematosus (SLE). The Company highlighted its key programs, including GRI-0621, an NKT cell modulator for IPF, and outlined significant upcoming milestones for 2024. Expected activities include reporting interim and topline results from biomarker studies and filing IND applications for GRI-0803. This engaging presentation underscores GRI Bio's commitment to data-driven progress in treating severe inflammatory conditions.
Read more →GRIGRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
GRI Bio, Inc. presented positive preclinical data on its NKT cell modulators, GRI-0803 and GRI-0124, targeting systemic lupus erythematosus (SLE) at a recent congress. The data indicated effectiveness in inhibiting lupus nephritis and improving overall survival in preclinical studies. GRI Bio is aiming for an IND filing for GRI-0803 in Q3 2024, with topline data expected by Q4 2024. The results underscore the potential of these molecules to provide safe and effective treatment options for SLE, an area with significant unmet needs.
Read more →GRIGRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
GRI Bio, Inc. presented positive preclinical data on GRI-0621, a novel treatment for idiopathic pulmonary fibrosis (IPF), at the 2024 ATS International Conference. The data indicated that GRI-0621 can reduce inflammation and fibrosis through the inhibition of iNKT cell activity in mouse models. The company plans to move forward with a Phase 2a biomarker study, with interim data anticipated in Q3 2024 and topline results in Q4 2024, further showing their commitment to advancing therapeutic solutions for IPF.
Read more →GRIGRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
GRI Bio, Inc. will present at the Alliance Global Partners' 2024 Healthcare Company Showcase on May 21, 2024. CEO Marc Hertz will participate in a fireside chat, discussing the company's innovative NKT cell modulators aimed at treating inflammatory and autoimmune diseases. The event will be available via live webcast on GRI Bio's website.
Read more →GRIGRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
GRI Bio, Inc. has announced that CEO Marc Hertz will participate in a fireside chat at the 2024 Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024. The event will be webcasted live on the company’s website. GRI Bio specializes in developing Natural Killer T cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. Their lead product, GRI-0621, targets idiopathic pulmonary fibrosis, addressing significant unmet medical needs in the field.
Read more →GRIGRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
GRI Bio reported its Q1 2024 financial results and outlined progress in its clinical trials. The company anticipates interim data from its Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis (IPF) by Q3 2024, with topline results expected in Q4. GRI Bio is also advancing its GRI-0803 program for systemic lupus erythematosus (SLE), with an IND filing planned for H2 2024. The firm has bolstered its financial position with a recent public offering and made strides with patent protection for its NKT cell modulators.
Read more →GRIGRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF
GRI Bio has released its financial results for Q1 2024, reporting a net loss of $1.9 million. The company is making advancements with its lead program, GRI-0621, which targets Idiopathic Pulmonary Fibrosis, with interim data expected in Q3 2024. Additionally, GRI Bio has received patent approvals and is preparing to file an Investigational New Drug application for GRI-0803 in the second half of 2024. The company has sufficient cash reserves to support operations into Q3 2024 while they continue to develop their innovative therapies.
Read more →GRIGRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
GRI Bio, Inc. announced that its abstracts have been accepted for presentation at the 14th International Congress on Autoimmunity, scheduled for May 17-20, 2024, in Ljubljana, Slovenia. The presentations will focus on the immune regulation related to CD8 Treg and Type 2 NKT cell mechanisms, highlighting the company's commitment to advancing treatments for inflammatory and autoimmune diseases. GRI Bio, known for its pipeline targeting NKT cell modulators, aims to address unmet needs in conditions such as idiopathic pulmonary fibrosis and systemic lupus erythematosus.
Read more →GRIGRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
GRI Bio, Inc. announced its participation in the upcoming LIVE! with Webull Corporate Connect Virtual Biotech Investment Webinar on May 1, 2024. CEO Marc Hertz, PhD, will present insights on GRI Bio's innovative pipeline, which includes NKT cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. The company is advancing its lead program, GRI-0621, as a promising oral treatment for idiopathic pulmonary fibrosis. GRI Bio's extensive portfolio of over 500 proprietary compounds highlights its ongoing commitment to addressing significant unmet medical needs.
Read more →GRIGRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
GRI Bio, Inc. announced the issuance of a patent by the Korean Intellectual Property Office for its proprietary Natural Killer T (NKT) cell modulators aimed at treating inflammatory conditions. The patent specifically protects compositions and methods related to modulating invariant NKT cells in preventing and treating liver inflammation and fibrosis. This development is seen as a significant enhancement to GRI Bio's growing intellectual property estate, as they advance their pipeline targeting inflammatory, fibrotic, and autoimmune diseases. The company is currently progressing its lead program, GRI-0621, through a Phase 2a clinical study for idiopathic pulmonary fibrosis.
Read more →GRIGRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
GRI Bio, Inc. has announced that its abstract will be presented at the 2024 American Thoracic Society International Conference scheduled for May 17-22, 2024, in San Diego, CA. The poster titled "Altered NKT Cell Populations in the Airways of Patients With IPF" will be presented by the Chief Medical Officer Albert Agro, PhD. This opportunity highlights GRI Bio's focus on developing treatments for inflammatory and fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). The company aims to change treatment methodologies and address unmet needs with its novel therapies targeting NKT cell activity.
Read more →GRIGRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
GRI Bio has announced its financial results for 2023, highlighting a net loss of $13 million. The company expects to advance its lead program GRI-0621 for Idiopathic Pulmonary Fibrosis with interim data projected for H1 2024. A public offering raised $5.5 million, extending its cash runway into Q3 2024. Regulatory achievements include FDA clearance for the IND application, indicating progress in their development pipeline.
Read more →GRIGRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
GRI Bio, Inc. will present at the MedInvest Biotech & Pharma Investor Conference on April 3, 2024. CEO Marc Hertz will discuss the company's innovative pipeline of NKT cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. The event will include a live webcast and opportunities for one-on-one meetings with investors.
Read more →GRIGRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
GRI Bio, Inc. will present at the MedInvest Biotech & Pharma Investor Conference on April 3, 2024. CEO Marc Hertz will address attendees in New York City, showcasing GRI's innovative therapies for inflammatory, fibrotic, and autoimmune diseases. The company is also offering one-on-one meetings for interested investors. GRI Bio's lead program focuses on treating Idiopathic Pulmonary Fibrosis (IPF) with a novel oral therapeutic.
Read more →GRIGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
GRI Bio, Inc. has announced a notice of allowance for a Canadian patent related to its proprietary Natural Killer T (NKT) cell modulators. This patent is significant as it covers methods for the prevention and treatment of inflammatory conditions, specifically targeting the modulation of NKT cells. The company is focused on addressing high-value indications such as inflammatory and fibrotic diseases. Additionally, GRI Bio is progressing with its lead program, GRI-0621, currently in Phase 2a trials for idiopathic pulmonary fibrosis.
Read more →GRIGRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
GRI Bio received authorization from the UK's MHRA to initiate a Phase 2a biomarker study for GRI-0621, targeting Idiopathic Pulmonary Fibrosis (IPF). This study follows ongoing research in the U.S., with interim data expected in early 2024. The trial aims to establish the safety and tolerability of GRI-0621 and may offer a new treatment avenue for IPF patients who currently have limited options. The company plans a collaboration with the NIHR Respiratory Translational Research Collaboration to facilitate study enrollment in the UK.
Read more →GRIGRI Bio Announces Pricing of $5.5 Million Public Offering
GRI Bio, Inc. announced the pricing of its public offering, set to raise approximately $5.5 million through the sale of 5 million shares at $1.10 each. The offering will also include warrants for investors, exercisable at the same price. The proceeds are intended for working capital and general corporate purposes, with the closing expected around February 6, 2024. The company focuses on developing novel therapies for inflammatory, fibrotic, and autoimmune diseases, particularly leveraging its expertise in NKT cell modulation.
Read more →GRIGRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio, Inc. has begun patient enrollment in a Phase 2a biomarker study for GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF). The company anticipates interim data in the first half of 2024 and topline results later in the year. GRI-0621 is being developed as a once-daily oral capsule, potentially expanding into additional fibrotic indications. The study will include approximately 36 subjects and assess safety, tolerability, and pharmacodynamic activity.
Read more →GRIGRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio has received FDA clearance for its IND application for GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF). The company plans to initiate a Phase 2a biomarker study with patient enrollment expected before the year ends. GRI-0621 is positioned as a novel oral treatment that may address significant unmet needs in IPF management.
Read more →GRIGRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio has received FDA clearance for its Investigational New Drug application for GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF). The company plans to begin a Phase 2a biomarker study before the end of 2023, involving approximately 36 subjects. This study will assess the safety and tolerability of GRI-0621, with interim data expected in the first half of 2024. GRI-0621 represents a new oral therapeutic approach targeting NKT cells, which are critical regulators in inflammatory diseases.
Read more →GRIGRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GRI Bio reported its third-quarter 2023 financial results, highlighting advancements in its clinical programs for idiopathic pulmonary fibrosis (GRI-0621) and systemic lupus erythematosus (GRI-0803). The company is on track to launch a Phase 2a biomarker study for GRI-0621 by the end of 2023, with interim data expected in the first half of 2024. GRI Bio has also entered a collaboration with the UK's National Institute for Health and Care Research to further its research initiatives. Overall, GRI Bio aims to provide innovative treatments for severe autoimmune and fibrotic diseases.
Read more →GRIGRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
GRI Bio presented data at the 7th Annual Antifibrotic Drug Development Summit supporting its lead program, GRI-0621, which targets iNKT cells to treat inflammatory, fibrotic, and autoimmune diseases. The compound has shown promising results in reducing lung damage and fibrosis in preclinical trials. GRI Bio is preparing to launch a Phase 2a biomarker study on GRI-0621 aimed at idiopathic pulmonary fibrosis (IPF) and is optimistic about its future applications. The company is focused on transforming treatment approaches for diseases associated with inflammation and fibrosis.
Read more →GRIGRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
GRI Bio presented new translational data at the 2023 Pittsburgh-Ireland International Lung Conference, highlighting the positive correlation between NKT cells and airway macrophages in idiopathic pulmonary fibrosis (IPF) patients. The company is preparing to initiate a Phase 2a biomarker study for its lead program, GRI-0621, a type 1 invariant NKT antagonist, which is positioned as a potential treatment for IPF. While the findings are promising, they note that the correlation with lung function parameters was not statistically significant in the small study mentioned. This data reinforces the need for further research into NKT cells' role in IPF pathology.
Read more →GRIGRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
GRI Bio has announced a partnership with the NIHR Respiratory Translational Research Collaboration, aiming to enhance research into Natural Killer T cell modulators to treat idiopathic pulmonary fibrosis (IPF). This collaboration will provide access to leading UK research centers, facilitating complex multi-center studies for developing GRI-0621, GRI Bio's leading program. Preliminary data suggest that GRI-0621 may effectively improve fibrosis in patients. The company is also set to leverage a 505(b)(2) regulatory pathway to advance clinical studies.
Read more →GRIGRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
GRI Bio, a biotechnology firm focused on therapies targeting NKT cells for inflammatory and autoimmune diseases, announced participation in the Virtual Investor Ask the CEO Conference on October 24, 2023. CEO Marc Hertz will address investor questions during this event, providing insights into the company's innovations and pipeline. GRI Bio's lead program, GRI-0621, is being developed for idiopathic pulmonary fibrosis, aiming to meet significant unmet medical needs. The company continues to build its pipeline with additional novel compounds in development.
Read more →GRIGRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
GRI Bio has announced the publication of a comprehensive review on the role of type 1 invariant NKT (iNKT) cells in fibrotic diseases, highlighting their importance in modulating inflammatory cascades. The company's lead program, GRI-0621, is progressing towards a Phase 2a biomarker study for idiopathic pulmonary fibrosis (IPF), aiming to launch before the end of 2023. This review provides insights into the mechanisms of fibrosis and underscores the potential of targeting iNKT cells to interrupt disease progression.
Read more →GRISeptember Is Pulmonary Fibrosis Awareness Month: Here’s What One Company Is Doing To Develop A Treatment For This Deadly Disease
September is Pulmonary Fibrosis Awareness Month, highlighting the urgent need for treatments for Idiopathic Pulmonary Fibrosis (IPF). GRI Bio is focused on developing GRI-0621, a drug that targets iNKT cells to potentially halt disease progression. The company is nearing IND filings for a phase 2a biomarker study, supported by a collaboration with the Respiratory Translational Research Collaboration.
Read more →GRIGRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
GRI Bio, Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023. The CEO, Marc Hertz, will discuss the company's innovative pipeline of Natural Killer T cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. Following the presentation, GRI Bio's management will hold virtual one-on-one meetings with qualified investors. The company's lead program targets idiopathic pulmonary fibrosis, addressing a serious disease with significant unmet need.
Read more →GRIIPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution?
GRI Bio is developing GRI-0621, a promising therapy for Idiopathic Pulmonary Fibrosis (IPF). This drug targets iNKT cells to inhibit inflammation and fibrosis, potentially improving patient outcomes. With a favorable safety profile and extensive IP protection, GRI-0621 may offer a new treatment avenue for this severe condition, which currently has a poor prognosis.
Read more →GRIGRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus
GRI Bio is advancing treatments for Idiopathic Pulmonary Fibrosis (IPF) and Lupus through innovative therapies targeting NKT cells. Their lead program, GRI-0621, aims to provide a novel oral treatment for IPF, addressing significant unmet needs. The company is also developing a pipeline for systemic lupus erythematosus, setting it apart from competitors in the biopharmaceutical sector.
Read more →GRIGRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
GRI Bio, Inc. has entered into an asset purchase agreement with Aardvark Therapeutics for the sale of its legacy product ADAIR. Aardvark will acquire global development and commercialization rights to ADAIR and utilize its formulation technology for future pipeline projects. GRI Bio will receive an upfront payment along with potential milestone payments up to $80 million, allowing the company to focus on its core assets. However, ADAIR's recent clinical trials did not support regulatory approval, raising concerns about the product's future viability.
Read more →GRIGRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update
GRI Bio (NASDAQ: GRI) announced its second quarter financial results, highlighting advancements in its clinical pipeline targeted at inflammatory and autoimmune diseases. The company is set to launch a Phase 2a study for its lead candidate GRI-0621, focused on idiopathic pulmonary fibrosis (IPF). GRI Bio also completed a merger with Vallon Pharmaceuticals, enhancing its corporate structure and resources. However, the financial report revealed a net loss and escalating operational costs, notably related to the merger and increased staffing.
Read more →GRIGRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
GRI Bio, Inc. presented encouraging preclinical data on GRI-0803 at The Autoimmunity Conference. The data showed that oral administration of GRI-0803 inhibited lupus nephritis and improved overall survival in animal models. The company plans to initiate a Phase 1a/b study for systemic lupus erythematosus in the first half of 2024, with topline results expected later in the year. GRI-0803 targets type 2 NKT cells, aiming to address the significant unmet needs in lupus therapies.
Read more →GRIGRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference
GRI Bio, Inc. announced its participation in Benzinga's Virtual Biotech Conference, where CEO Marc Hertz will discuss the company's innovative therapies targeting inflammatory and autoimmune diseases. The company is focused on developing NKT cell modulators, including its lead program GRI-0621 for idiopathic pulmonary fibrosis. GRI Bio aims to change treatment paradigms in these areas.
Read more →GRIGRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference
GRI Bio, Inc. announced its participation in Benzinga's Virtual Biotech Conference, which will take place on August 3, 2023. The company's CEO, Marc Hertz, will engage in a fireside chat discussing GRI Bio's innovative therapeutic pipeline focused on using Natural Killer T (NKT) cell modulators for treating inflammatory diseases. The event highlights GRI Bio's commitment to developing novel therapies in areas with significant unmet medical needs. However, the company also acknowledges various risks inherent in this development process, including potential regulatory and financial challenges.
Read more →GRIGRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
GRI Bio, Inc. will present at the Virtual Investor - The GRI Opportunity Spotlight Event on July 27, 2023. The management team will discuss their innovative approach to treating inflammatory diseases by targeting NKT immune cells. Investors can submit questions live during the event, which will also be available for replay afterward.
Read more →GRIGRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
GRI Bio, Inc., a biotechnology company, is set to present at the Virtual Investor – The GRI Opportunity Spotlight Event on July 27, 2023. The event will feature discussions led by key management members about GRI Bio's innovative approach to treating inflammatory, fibrotic, and autoimmune diseases through Natural Killer T (NKT) cell modulators. Notably, the company is developing its lead program, GRI-0621, an inhibitor targeting iNKT cell activity for idiopathic pulmonary fibrosis. A live video webcast of the presentation will be available on the company's website, offering opportunities for audience engagement.
Read more →GRIGRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series
GRI Bio, Inc. (NASDAQ: GRI) announced the participation of its management team in the Virtual Investor Summer Spotlight Series on July 11, 2023. The presentation will showcase GRI Bio's pipeline, emphasizing their innovative approach towards treating inflammatory and autoimmune diseases with NKT cell modulators. The event will be available to investors through a live webcast, highlighting the company's ongoing efforts in biotechnology.
Read more →GRIGRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
GRI Bio has successfully issued a U.S. patent for GRI-0621, its leading candidate for treating idiopathic pulmonary fibrosis (IPF). This patent provides broad coverage for the treatment methods involving Retinoic Acid Receptor agonists and extends patent protection until 2032. The company is prioritizing the development of its patent portfolio and announces plans for a Phase 2a study of GRI-0621 in the second half of 2023. GRI Bio continues to enhance its global intellectual property, emphasizing its commitment to addressing inflammatory and fibrotic diseases.
Read more →GRIGRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
GRI Bio, Inc. (NASDAQ: GRI) has announced its participation in the Healthcare Virtual Conference hosted by Maxim Group LLC on June 22, 2023. Marc Hertz, the CEO, will lead a presentation that showcases GRI Bio's innovative pipeline of Natural Killer T cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases. The conference is expected to feature various biotechnology and medical device companies discussing key developments in the sector. GRI Bio is particularly focused on addressing significant unmet medical needs with its lead program aimed at idiopathic pulmonary fibrosis.
Read more →GRIGRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
GRI Bio, Inc. has announced a corporate rebranding along with the launch of its new website, aiming to better reflect its vision and expand its market presence. The company is focused on developing Natural Killer T (NKT) cell modulators targeting inflammatory, fibrotic, and autoimmune diseases. GRI Bio is progressing with its lead candidate GRI-0621 for idiopathic pulmonary fibrosis and has plans for a Phase 2a biomarker study. Additionally, the company is developing GRI-0803 for autoimmune disorders, with a diverse pipeline of potential therapies.
Read more →GRIGRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators
GRI Bio, Inc. has announced significant advancements in its clinical pipeline focused on NKT cell modulators for treating inflammatory and autoimmune diseases. The company is emphasizing its lead programs, GRI-0621 and GRI-0803, which aim to address key unmet needs in idiopathic pulmonary fibrosis and systemic lupus erythematosus. Upcoming milestones include the launch of a Phase 2a biomarker study in H2 2023 and interim data reporting in H1 2024. GRI Bio's innovative approach may provide novel treatment options and significantly impact patient health in these challenging conditions.
Read more →GRI▲ +18%on this news
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event
GRI Bio, Inc., a biotechnology company specializing in Natural Killer T (NKT) cell modulators, announced its participation in the Virtual Investor New to the Street Event on May 3, 2023. Company executives will present a corporate overview and outline their business outlook, with a live Q&A session for investors. GRI Bio is focused on treating inflammatory and autoimmune diseases, and its lead program targets idiopathic pulmonary fibrosis, addressing significant unmet medical needs. The company emphasizes the potential risks associated with future financial health and regulatory approvals.
Read more →GRI▼ -5.5%on this news· ran to -31% by day 1shared move
GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer
GRI Bio, Inc. has announced the appointment of Leanne Kelly as Chief Financial Officer. With over 20 years of experience in finance and management, Kelly previously served as CFO at Vallon Pharmaceuticals, which recently merged with GRI. CEO Marc Hertz expressed confidence in Kelly's ability to contribute significantly during GRI's transition to being a publicly traded entity. Kelly aims to establish GRI's presence in the investment community and drive long-term value.
Read more →GRIGRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry
GRI Bio, Inc. has announced the appointment of David Szekeres, Roelof Rongen, and Camilla V. Simpson to its Board of Directors, totaling over 75 years of life sciences experience. This marks a pivotal transformation for GRI Bio, particularly following its merger with Vallon Pharmaceuticals. The executives are expected to drive the company's growth in developing NKT cell modulators for treating autoimmune and fibrotic diseases. GRI Bio's innovative therapies aim to address significant unmet medical needs, with a leading program targeting idiopathic pulmonary fibrosis.
Read more →GRIVallon Pharmaceuticals Completes Merger with GRI Bio, Inc. Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T ("NKT") modulating therapies for the treatment of inflammatory
Vallon Pharmaceuticals has completed its merger with GRI Bio, resulting in a new company named GRI Bio, Inc. This entity will focus on innovative Natural Killer T cell modulating therapies aimed at treating inflammatory, fibrotic, and autoimmune diseases. With an investment of approximately $15 million, GRI Bio plans to advance its pipeline, particularly through clinical trials for its lead candidate GRI-0621 and another compound aimed at autoimmune disorders. The new entity will begin trading under the ticker symbol 'GRI' starting April 24, 2023.
Read more →GRIVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event Live video webcast on Tuesday
Vallon Pharmaceuticals and GRI Bio announced their participation in the Virtual Investor 2023 Companies to Watch Event, scheduled for January 17, 2023. During the event, executives from both companies will discuss a definitive merger agreement under which GRI Bio will merge with Vallon in an all-stock transaction. This merger aims to enhance GRI Bio's focus on developing NKT cell modulators targeting inflammatory and autoimmune diseases. The transaction is expected to close in the first quarter of 2023, indicating timely progress in their strategic plans.
Read more →GRIVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators Combined company will operate as GRI Bio and advance innovative pipeline of Natural Killer
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators Combined company will operate as GRI Bio and advance innovative pipeline of Natural Killer T (NKT) regulating therapies for the treatment of inflammat
Read more →GRIVallon Pharmaceuticals Reports Third Quarter 2022 Financial Results PHILADELPHIA, PA
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results PHILADELPHIA, PA, November 3, 2022 - Vallon Pharmaceuticals, Inc. (NASDAQ VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that a
Read more →GRIDocument Exhibit 10.1 Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update PHILADELPHIA, PA, July 28 , 2022 - Vallon Pharmaceuticals, Inc. (NASDAQ VLON), ("Vallon" or the "Co
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update PHILADELPHIA, PA, July 28, 2022 - Vallon Pharmaceuticals, Inc. (NASDAQ VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the devel
Read more →GRIVallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering PHILADELPHIA, PA, May 13 , 2022 - Vallon Pharmaceuticals, Inc. (NASDAQ VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical compa
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering PHILADELPHIA, PA, May 13, 2022 - Vallon Pharmaceuticals, Inc. (NASDAQ VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that
Read more →GRIDocument Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR - Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will targe
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR - Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will target the growing Adderall segment of the $9 billion U.S. ADHD market
Read more →GRIVallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and tre
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development prog
Read more →GRIVallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements - Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formu
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements - Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR -
Read more →GRIVallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall
Read more →GRIVallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update - Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent pl
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update - Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunit
Read more →GRIVallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval - Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021 - Target NDA filing in Q2 2022 for a potential abuse-deterrent alte
Read more →GRIWorking to Reduce ADHD Medication Abuse NASDAQ: VLON vallon - pharma.com Investor Presentation February 2021
Working to Reduce ADHD Medication Abuse NASDAQ: VLON vallon - pharma.com Investor Presentation February 2021 Forward Looking Statements This presentation contains projections of, and assumptions regarding, future events reflecting our beliefs and expectations . Such events may o
Read more →GRIVallon Pharmaceuticals Announces Pricing of Initial Public Offering
Vallon Pharmaceuticals Announces Pricing of Initial Public Offering PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are design
Read more →Competitive Position
How GRI ranks across every disease it competes inCompetitive Position is a premium feature
See how GRI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial